Astrazeneca Plc · LSE:AZN
Astrazeneca — JP Morgan Healthcare Conference 2013
15 slides from Astrazeneca's conference presentation, Jan 9, 2013
Slide 1: Partnering for Growth
Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013
Slide 2: Agenda
Partnering for Growth Agenda • Our platforms for growth • Partnering strategy and capabilities • Building on our strong position in Diabetes and Respiratory and Inflammation 1
Slide 3: Platforms for Growth
Platforms for Growth • Cardiovascular: (Brilinta, Crestor) • Diabetes (Onglyza, Kombiglyze, Forxiga, Byetta/Bydureon) On-market growth franchises • Respiratory (Symbicort, Pulmicort) • Oncology (Iressa, Faslodex) • Japan Primary Care (Nexium, Symbicort, Crestor) • Invest behind current brand portfol
Slide 4: Portfolio highlights 2011/2012
Portfolio highlights 2011/2012 Phase III/LCM Submitted New indications Launched/Approved naloxegol Renal impairment Further markets USA, Europe Europe USA, Canada, Brazil CAZ AVI Add-on to insulin China USA Russia Europe fostamatinib 1st Line Japan Europe, Canada, Brazil Further markets Japan lesinu
Slide 5: Agenda
Partnering for Growth Agenda • Our platforms for growth • Partnering strategy and capabilities • Building on our strong position in Diabetes and Respiratory and Inflammation 4
Slide 6: Working in collaboration is key part of our strategy
Working in collaboration is key part of our strategy Partnering is a core business priority and a long-term commitment. Approximately 81 deals completed in 2012 with industry and academia Three global, late-stage deals completed in 2012 (Amgen, Ardea, and BMS/Amylin) 40% of our pipeline is currently
Slide 7: Main areas of interest and recent product launches/partners
Main areas of interest and recent product launches /partners FORXIGA Cardiovascular Gastrointestinal Oncology Respiratory & Inflammation Partnering Infection areas of Neuroscience Interest New Personalised Opportunities Healthcare & BioMarkers Science & Technology 6
Slide 8: Expanding pipeline of key partnerships
Expanding pipeline of key partnerships Phase III/ Launched/ Phase II Registration Approved (2012) Oncology CNS Oncology Tremelimumab MEDI-575 Selumetinib Naloxegol RANMARK (Japan) Respiratory & Inflammation Diabetes Fostamatinib AZD2115 AMG139 AZD8683 AZD5423 AMG157 FORXIGA AMG181 AMG557 Lesinurad M
Slide 9: As a Commercial partner we bring....
8 As a Commercial partner we bring.... Truly global commercial operations footprint with both primary and specialty care focus A large and growing presence in emerging markets including China, Brazil, Russia Sales, marketing and medical excellence to tailor brands and drive performance in 100
Slide 10: AZ's Global scale and reach
AZ’s Global scale and reach Global in-licensing and co-marketing Sales 9M 2012 of Crestor in Japan 40 innovative medicines licensed in Russia with Shionogi New manufacturing plan Co-promotion deals with Daiichi Predictive science centre in Sankyo and St Petersburg Astellas Americas China $8.6bn $1.1
Slide 11: As a Development partner we bring...
As a Development partner we bring... 75% of our portfolio applies a personalised healthcare approach 87% of projects apply new methods of clinical design and interpretation 90% of pipeline addresses payer evidence to support reimbursement Competitive regulatory labeling linked to claims Worl
Slide 12: Agenda
Partnering for Growth Agenda • Our platforms for growth • Partnering strategy and capabilities • Building on our strong position in Diabetes and Respiratory and Inflammation 11
Slide 13: AZ-BMS collaboration has built strong portfolio across diabetes treatment continuum
AZ- BMS collaboration has built strong portfolio across diabetes treatment continuum Diabetes Class Product Indication Status Original Collaboration Type 2 Diabetes Marketed agreement in DPP-IV 2007 Inhibitor Type 2 Diabetes Marketed Development and launch of DDPIV & SGLT2 Type 2 SGLT-2 FORXIGA Diab
Slide 14: AMGEN Collaboration to jointly develop and commercialise inflammation portfolio
AMGEN Collaboration to jointly develop and commercialise inflammation portfolio • Collaboration to develop and commercialise five monoclonal antibodies; leverages complementary Amgen and AZ/Medimmune capabilities and market positions • Potential to deliver treatments for up to ten potential indicati
Slide 15: For more information about partnering with AstraZeneca
For more information about partnering with AstraZeneca, visit For more information about partnering with AstraZeneca, visit astrazeneca.com/partnering